Canaccord Genuity Maintains a 'Buy' on Amicus Therapeutics (FOLD); Rolling Out New Amigal Trials With GSK's Support
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' on Amicus Therapeutics (Nasdaq: FOLD), PT $7.
Canaccord analyst says, "Amigal pivotal data in Q3/11 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Amigal pivotal data in Q3/11 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
